Mark Levy, M.D. an orthopedic surgeon and founder of Expanding Orthopedics, said in the October 22, 2014 news release, “My vision, since I founded the company, was to develop a unique family of expandable devices covering spine and trauma applications, creating a new standard of care. This 13th granted U.S. patent covers innovative technologies in the area of expandable interbody cages and VCF [vertebral compression fractures] solutions. This confirms our ability to develop together, with our advising surgeons, state-of-the-art devices which, ultimately, provide patients with improved clinical outcome.”
Expanding Orthopedics Expands Patent Line

Ofer Bokobza, EOI’s CEO, commented, “This new patent demonstrates our continuous commitment to innovation and reinforces our position as a leading innovator in the area of expandable devices. While our Sales & Marketing team is currently focused on bringing the FDA cleared FLXfit 3D expandable cage to the U.S. market, our engineering team continues to work on the next generation of expandable devices to meet surgeons’ evolving needs. We are dedicated to a continuous pursuit of raising the bar in providing a new standard of care in spine surgery.”
Bokobza told OTW, “This patent covers several claims and devices among them are expandable cage and expandable VCF device. The company is now focused on the commercializing stage of the FLXfit, our unique 3D expandable cage, in the U.S. We have signed our first distribution agreement in the U.S. and are now in the process of signing additional distributors in the U.S.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.